+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Forecast 2024-2030- Product Image
Global Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Forecast 2024-2030- Product Image
Sale

Global Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968597
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Non-Hodgkin Lymphoma Treatment Market size was estimated at USD 8.20 billion in 2023, USD 8.84 billion in 2024, and is expected to grow at a CAGR of 7.91% to reach USD 13.98 billion by 2030.

Non-Hodgkin Lymphoma refers to a type of cancer that begins and develops in the lymph nodes and lymphatic tissue found in organs, including the stomach and intestines. Swollen lymph nodes in the neck, abdominal pain or swelling, chest pain, coughing, or trouble breathing are some common symptoms of the disease. Treatment options for non-Hodgkin lymphoma (NHL) include chemotherapy, radiation, plasmapheresis targeted therapy, and stem cell transplant. Newer treatment options for non-Hodgkin lymphoma are focused on making personalized medications, targeted drugs, and immunotherapy engineered to attack cancer cells specifically.

Changing lifestyles and rising incidences of obesity have led to a surge in the number of patients suffering from cancers and tumors. Additionally, the launch of promising drugs and the number of drug approvals for lymphomas is rapidly increasing. However, the high cost of availing cancer treatment options reduces the accessibility of treatment options. Furthermore, stringent regulations for cancer treatment options have dissuaded research institutions from investing in cancer treatment research and have hampered the commercialization of novel drugs. The government's focus on increasing awareness about cancer and its treatment options is gaining traction and can aid in reducing the number of barriers posed by complex regulations. Biotechnology, and pharmaceutical institutions and companies have introduced targeted biological therapies and drug options for cancer, such as antibody-drug conjugate and proteasome inhibitors.

Regional Insights

Significant Americas countries, such as the USA and Canada, are associated with a higher awareness of the availability of treatment options and reimbursement plans for cancer treatment. The Americas market for NHL treatment is driven by the increasing number of cancer care centers and oncology specialists in the region. Additionally, Americas countries are characterized by the presence of major biotechnology and pharmaceutical companies and a large number of treatment solutions introduced for Non hodgkin lymphoma. Countries in Asia, including China, have expanded their focus on increasing the number of drug approvals for cancer treatment. Governments are rapidly investing their efforts to improve awareness of lymphomas and their symptoms.

European nations have well-established academic and research institutions that are actively involved in research and development activities concerning non-Hodgkin lymphoma and other cancers. Additionally, the growing number of clinical trials and collaborations between biotechnology companies and governments has been a significant driving factor towards the introduction of novel treatment therapies.

Market Trends by Segment

  • Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
  • Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
  • End-user: Increasing adoption of novel strategies for NHL treatment in hospitals

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie Inc. has announced that the U.S. Food and Drug Administration (FDA) has recently granted approval for EPKINLYTM (epcoritamab-bysp) for the treatment of diffuse large B-cell lymphoma (DLBCL) in adults. This includes DLBCL that arises from high-grade B-cell lymphoma and indolent lymphoma after two or more lines of systemic therapy. EPKINLY is the only T-cell-engaging bispecific antibody for non-Hodgkin lymphoma treatment approved by the FDA.

Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

Janssen Biotech Inc., a Johnson & Johnson Services, Inc. subsidiary, collaborated with Cellular Biomedicine Group Inc. (CBMG) on developing and commercializing CAR T-cell therapies specifically designed for B-cell malignancies. These autologous CAR-Ts, directed towards CD20, have exhibited promising response rates in Phase 1 clinical trials involving non-Hodgkin's lymphoma (NHL) patients. This collaboration between Janssen Biotech Inc. and Cellular Biomedicine Group Inc. represents a significant step forward in advancing CAR T-cell therapies for treating B-cell malignancies, particularly in the context of non-Hodgkin lymphoma.

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

Biogen Inc. and Genentech, a Roche Group member, have agreed on the commercialization and economic sharing of glofitamab, a non-Hodgkin lymphoma treatment. Under this agreement, Biogen receives tiered royalties based on potential net sales in the United States without any payment obligations. This partnership revolves around developing an antibody that targets CD20 and extends the existing collaboration between both companies.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

This research report offers invaluable insights into various crucial aspects of the Non-Hodgkin Lymphoma Treatment Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
5.1.1.2. The launch of promising drugs and drug approval for lymphomas
5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
5.1.2. Restraints
5.1.2.1. High cost of the treatment and certain side effects
5.1.3. Opportunities
5.1.3.1. Increase in research and development of therapeutic drugs against the disease
5.1.3.2. Rising investments from government and non-profit organizations
5.1.4. Challenges
5.1.4.1. Stringent regulations for cancer treatment options
5.2. Market Segmentation Analysis
5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation Therapy
6.5. Stem Cell Transplantation
6.6. Targeted Therapy
7. Non-Hodgkin Lymphoma Treatment Market, by Application
7.1. Introduction
7.2. Diffuse Large B-cell Lymphoma
7.3. Follicular Lymphoma
7.4. Mantle Cell Lymphoma
8. Non-Hodgkin Lymphoma Treatment Market, by End-User
8.1. Introduction
8.2. Cancer Centers
8.3. Home Care
8.4. Hospitals
9. Americas Non-Hodgkin Lymphoma Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 51. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 52. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 55. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 56. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 57. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 58. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 59. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 60. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 61. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 62. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 63. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 64. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 65. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 66. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 71. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 72. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 73. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 74. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 80. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 82. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 85. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 86. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 87. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 88. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 89. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 90. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 91. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 92. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 93. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 94. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 95. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 96. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 97. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 100. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 103. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 104. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 105. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 106. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 107. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 108. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 109. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 110. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 111. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 112. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 115. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 118. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 121. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 122. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 123. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 124. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 127. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 128. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 129. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 130. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 133. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 134. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 135. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 136. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 139. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 142. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 143. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 144. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 145. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 146. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 147. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 148. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 151. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 152. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 153. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 154. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 163. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 164. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 165. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 166. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 167. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 168. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 169. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 170. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 171. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 172. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 173. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 174. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 175. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 176. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 177. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 178. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 179. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 180. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 181. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 182. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 183. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 184. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 185. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 186. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 187. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 188. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 189. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 190. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 191. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 192. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 195. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 196. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 197. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 198. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 199. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 200. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 201. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 202. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 203. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 204. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 207. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 208. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 209. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 210. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 213. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 214. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 215. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 216. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 217. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 218. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 219. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 220. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 221. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 222. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 223. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 224. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 225. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 226. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 227. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 228. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 229. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 230. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 231. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 234. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 237. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 238. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 239. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 240. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 244. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 246. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 250. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 252. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 253. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 254. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 255. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 256. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 257. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 258. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 261. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 262. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 263. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 264. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 267. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 268. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 269. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 270. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 271. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 272. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 273. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 274. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 275. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 276. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 286. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 288. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 289. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 290. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • AstraZeneca PLC
  • Aurobindo Pharma
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Drugs Ltd.
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Janssen Global Services, LLC
  • Kyowa Kirin Co., Ltd.
  • Lupin Ltd.
  • Merck KGaA
  • Nordic Nanovector ASA by Thor Medical
  • Novartis AG
  • Pharmacyclics, LLC
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.98 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Global Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report By Cell Type (B-Cell Lymphoma and T-Cell Lymphoma), By Therapy Type (Radiation Therapy, Chemotherapy, Targeted Therapy, and Others), By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Global Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report By Cell Type (B-Cell Lymphoma and T-Cell Lymphoma), By Therapy Type (Radiation Therapy, Chemotherapy, Targeted Therapy, and Others), By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • 193 Pages
  • Global
From
B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2024 - Product Image

B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Non-Hodgkin Lymphoma Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Non-Hodgkin Lymphoma Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 112 Pages
  • Global
From
CAR T-Cell Therapy for Non-Hodgkin's lymphoma- - Pipeline Insight, 2024 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's lymphoma- - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Non-Hodgkin Lymphoma Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Non-Hodgkin Lymphoma Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From

About the Non Hodgkin Lymphoma Drug Market

The Non Hodgkin Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. Non Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, and is the seventh most common cancer in the United States. Treatment for NHL typically involves chemotherapy, radiation, and targeted therapies. The Non Hodgkin Lymphoma Drug market is composed of a variety of drugs used to treat NHL, including monoclonal antibodies, small molecule drugs, and immunomodulators. These drugs are used to target specific proteins and pathways involved in the development and progression of NHL. Some of the major companies in the Non Hodgkin Lymphoma Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.